Teva has announced the US launch of Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients. The company licensed Adasuve from its developer, Alexza Pharmaceuticals in May 2013. Alexza’s Staccato thermal aerosol inhaler is the delivery device.
Teva Select Brands and Teva Women’s Health VP and General Manager Michael McHugh said, “The availability of orally inhaled Adasuve provides a rapid onset of action that quickly improves symptoms for patients and gives providers in enrolled hospitals another treatment choice. As part of our ongoing commitment to enhancing patient care and bringing new therapies and delivery systems to the market that fit within our areas of expertise, Teva is pleased to launch this new treatment choice that is aligned with Teva’s New Therapeutic Entities (NTE) program.”
Alexza President and CEO Thomas B. King commented, “We believe Teva is an excellent commercial partner for Adasuve in the US, and we are confident of their commercial capabilities. We look forward to continuing our support of their launch efforts in the US.”
The FDA approved Adasuve at the end of December 2012 for administration only in healthcare facilities participating in the Adasuve Risk Evaluation and Mitigation Strategy (REMS) program.
Adasuve has been available in Germany since July 2013, and Grupo Ferrer, which has European marketing rights for the product, announced a launch in Austria in October 2013. In September 2013, Medivir acquired the rights to market Adasuve in the Nordic countries from Ferrer.
Read the Teva press release.
Read the Alexza press release.
